News | Stents Drug Eluting | January 10, 2017

Medinol Announces Positive 12-Month Trial Results for EluNIR Drug-Eluting Stent

Elastomer-coated DES shows identical target lesion failure, low definite/probable stent thrombosis rate compared to Resolute Integrity stent

Medinol, BIONICS study, 12-month results, TCT 2016, drug-eluting stent, EluNIR

January 10, 2017 — Medinol announced in December positive twelve-month clinical results from the BIONICS study. The study was conducted to evaluate EluNIR, Medinol's novel coronary stent system and the first ever elastomer-coated drug eluting stent (eDES), according to the company.

This global pivotal study enrolled 1,919 patients from 76 sites in eight countries. The BIONICS results were highlighted in the opening Late Breaking Trial session of the 28th annual Transcatheter Cardiovascular Therapeutics (TCT2016) scientific symposium, Oct. 29-Nov. 2 in Washington, D.C. The study data will be submitted to the U.S. Food and Drug Administration (FDA) to support the U.S. regulatory approval of EluNIR for the treatment of patients with narrowing or blockage of their coronary arteries.

The BIONICS study — a global, prospective, randomized, multicenter, non-inferiority clinical trial — was designed to include a "more comers" population, i.e. one that closely represents the real-world patient population. The EluNIR Stent (study name BioNIR) was compared to the Resolute Integrity Stent (1:1 randomization). Key results from the study include:

  • For its primary endpoint of target lesion failure (TLF), EluNIR demonstrated a rate of 5.4 percent at 12 months compared to an identical rate of 5.4 percent for Resolute (p=0.0013 for non-inferiority). TLF was defined as the composite of cardiac death, target vessel MI and clinically driven TLR; and
  • Good safety profile, with a low definite/probable stent thrombosis rate of 0.4 percent for EluNIR, compared to 0.8 percent for Resolute (p=NS), with no events beyond 30 days for EluNIR.    

"The BIONICS data validated that the EluNIR stent performed very well in a more broad, less selected 'more comers' population than has previously been studied for most other DES," said David Kandzari, M.D., F.A.C.C., director of interventional cardiology at Piedmont Heart Institute, Atlanta, and principal investigator for the BIONICS trial. "These results establish the excellent clinical performance of this stent, and we look forward to seeing the angiographic data over the next few months to further support its efficacy."

In addition to the BIONICS study, new twelve-month data from NIREUS, the European pivotal trial for EluNIR, were presented at TCT. The NIREUS study — a prospective, multi-center, randomized, non-inferiority pivotal study comparing EluNIR to the Resolute Integrity Stent — met its non-inferiority primary endpoint of angiographic in-stent late loss at six months. These data were presented at EuroPCR in May 2016. The recent twelve-month clinical data, presented TLF of 3.4 percent for EluNIR and 5.9 percent for Resolute (p=NS).These outcomes were consistent with the positive results of BIONICS.

For more information:

Related Content

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials
FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations
Technology | Stents | September 27, 2018
September 27, 2018 — Biotronik recently announced U.S.
Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init